Focused On-demand Library for Glutamate receptor 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P42263

UPID:

GRIA3_HUMAN

Alternative names:

AMPA-selective glutamate receptor 3; GluR-C; GluR-K3; Glutamate receptor ionotropic, AMPA 3

Alternative UPACC:

P42263; D3DTF1; Q4VXD5; Q4VXD6; Q9HDA0; Q9HDA1; Q9HDA2; Q9P0H1

Background:

Glutamate receptor 3, known as AMPA-selective glutamate receptor 3, GluR-C, GluR-K3, or Glutamate receptor ionotropic, AMPA 3, plays a pivotal role in the central nervous system. It functions as a ligand-gated ion channel, crucial for excitatory synaptic transmission. The binding of L-glutamate, an excitatory neurotransmitter, triggers a conformation change, opening the cation channel and converting the chemical signal to an electrical impulse.

Therapeutic significance:

The protein is linked to Intellectual developmental disorder, X-linked, syndromic, Wu type, characterized by moderate intellectual disability and other variable features. Understanding the role of Glutamate receptor 3 could open doors to potential therapeutic strategies for this disorder.